Collins Helen Louise
Known title: CHIEF MEDICAL OFFICERCIK: 0001701247
Associated companies
Transaction History
| ELVN | ▲ Buy | Option Exercise | 5,000 | $12K | 9/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 2,916 | $146K | 9/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,844 | $94K | 9/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 240 | $12K | 9/17/2026 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 5,000 | $12K | 8/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 3,900 | $228K | 8/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,100 | $65K | 8/17/2026 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 5,000 | $12K | 7/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 231 | $12K | 7/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 459 | $24K | 7/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 2,063 | $108K | 7/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 2,184 | $117K | 7/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 63 | $3K | 7/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,133 | $51K | 6/17/2026 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 5,000 | $12K | 6/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,268 | $54K | 6/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 2,599 | $114K | 6/17/2026 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 5,000 | $12K | 5/18/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 3,475 | $137K | 5/18/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 1,302 | $52K | 5/18/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 223 | $9K | 5/18/2026 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 5,000 | $12K | 4/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 140 | $6K | 4/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 2,419 | $115K | 4/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 2,441 | $117K | 4/17/2026 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 40,000 | $99K | 3/25/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 40,000 | $1.4M | 3/25/2026 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 5,000 | $12K | 3/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 5,000 | $139K | 3/17/2026 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 10,129 | $25K | 3/10/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 10,129 | $306K | 3/10/2026 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 29,871 | $74K | 3/9/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 29,871 | $897K | 3/9/2026 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 45,000 | $112K | 2/17/2026 | View on chart |
| ELVN | ▼ Sell | Open Market | 45,000 | $1.2M | 2/17/2026 | View on chart |
| ELVN | ▲ Buy | Grant | 25,000 | $0 | 2/12/2026 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 816 | $2K | 10/18/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 816 | $24K | 10/18/2024 | View on chart |
| ELVN | ▲ Buy | Option Exercise | 20,000 | $50K | 4/11/2024 | View on chart |
| ELVN | ▼ Sell | Open Market | 20,000 | $501K | 4/11/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Enliven's ENABLE-2 Trial Design Sparks New Questions
Enliven Therapeutics has clarified the design of its ENABLE-2 Phase 3 trial for relcobatinib in chronic myeloid leukemia, following questions raised by the trial’s structure. The company also confirmed FDA alignment on the study, while a separate patent dispute involving Halozyme and Merck has kept the leukemia treatment landscape in focus. These developments highlight the regulatory and strategic challenges Enliven faces as it moves toward clinical milestones.
Enliven's ENABLE-2 Trial Design Sparks New Questions. Enliven Therapeutics has clarified the design of its ENABLE-2 Phase 3 trial for relcobatinib in chronic myeloid leukemia, following questions raised by the trial’s structure. The company also confirmed FDA alignment on the study, while a separate patent dispute involving Halozyme and Merck has kept the leukemia treatment landscape in focus. These developments highlight the regulatory and strategic challenges Enliven faces as it moves toward clinical milestones.